secwatch.observer — SEC 8-K summary
======================================

Issuer:     HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK:        0000818033
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0000950170-25-028372
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Heron Q4 net income $3.6M; FY2024 rev $144.2M (+14%); guides 2025 rev $153-163M
-------------------------------------------------------------------------------

- Q4 2024 GAAP net income of $3.6M; full-year 2024 adjusted EBITDA of $8.6M.
- Full-year 2024 net revenue $144.2M (+14% YoY); Acute Care revenue up 57%, Oncology up 6%.
- 2025 guidance: net revenue $153-163M, adjusted EBITDA $0-8M.
- U.S. District Court upheld CINVANTI patents against Fresenius Kabi; patents expire 2035.
- Cash and investments $59.3M; ZYNRELEF VAN launched Dec 2024; Crosslink partnership.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818033/000095017025028372/0000950170-25-028372-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818033/000095017025028372/hrtx-20250227.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-028372

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer